BioSpace News Archive

Recently, CMAB Biopharma Inc’s partner Shanghai Junshi Biosciences Co., Ltd., announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection has been accepted by National Medical Products Administration.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

China Oncology Focus Limited, an affiliate of Lee’s Pharmaceutical Holdings Limited announced that its anti-PD-L1 antibody, Socazolimab, licensed from Sorrento to COF for the greater China territory, has been cleared to begin a multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.

Adlai Nortye, a global clinical-stage biopharmaceutical company, announced the formation of its new Scientific Advisory Board comprised of five internationally renowned experts.